Real Estate Archives - Page 6 of 26 - Boston Life Sciences Times

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

December 13, 2025

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

December 12, 2025

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

December 11, 2025

THIS WEEK'S STORIES

DexCare Appoints Rakshay Jain as Chief Product Officer to Advance Patient Navigation Platform

December 15, 2025

Acadia Pharmaceuticals Wins FDA Approval for DAYBUE STIX Powder Formulation for Rett Syndrome

December 12, 2025

InduPro Therapeutics announces strategic investment and research collaboration with Sanofi to advance bispecific candidate for autoimmune disorders

December 10, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Real Estate

Suffolk hires Roger Moore to strengthen healthcare construction leadership in California

Curium Pharma Selects Boston Seaport for New Global Headquarters

Instem Opens New Global Headquarters in Boston

Labshares Opens New Watertown Site, Doubles Its Footprint and Extends Shared-Lab Access to More Biotech Firms

Overture Life Opens First U.S. Clinical Lab and Operations Hub in Dallas as AI-Powered IVF Robotics Headquarters

Most Read

Linus Health appoints Julie Wood, MD, MPH, FAAFP, as senior medical director for clinician engagement

Fondazione Telethon, Orphan Therapeutics Accelerator outline non-profit pathway for U.S. access to ultra-rare gene therapy

Sōlaria Biō study links gut barrier health, inflammation and bone density in breakthrough findings

DexCare Appoints Rakshay Jain as Chief Product Officer to Advance Patient Navigation Platform

EDITOR PICKS

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

THIS WEEK'S STORIES

DexCare Appoints Rakshay Jain as Chief Product Officer to Advance Patient Navigation Platform

Acadia Pharmaceuticals Wins FDA Approval for DAYBUE STIX Powder Formulation for Rett Syndrome

InduPro Therapeutics announces strategic investment and research collaboration with Sanofi to advance bispecific candidate for autoimmune disorders

POPULAR CATEGORY

ABOUT US

FOLLOW US